News | October 04, 2021
Thermo Fisher opens biologics site in Lengnau, Switzerland
The state-of-the-art facility provides a pathway from development to large-scale biologics production
The state-of-the-art facility provides a pathway from development to large-scale biologics production
The company does not expect the outcome of this inspection to impact its plans
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
The company is eligible for 12 months exclusivity from launch
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
The submission is supported by results from the Phase 3b APEX study
Subscribe To Our Newsletter & Stay Updated
